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Introduction
Lung cancer is the leading cause of  cancer mortality in the US and the world, causing more cancer-related 
deaths than breast, prostate, and colon cancer — the next most common causes of  cancer mortality — 
combined (1). Lung adenocarcinoma (ADC), a subtype of  non–small cell lung carcinoma (NSCLC), is the 
most prevalent type of  lung cancer (1). Even with advances in early disease detection (2), the majority of  
lung ADC patients still succumb to disease. Whereas recent advancements with receptor tyrosine kinase 
inhibitors for targets, such as epidermal growth factor receptor (EGFR), have led to successful lung ADC 
treatments, other proto-oncogenes, such as those encoding RAS GTPases, remain poorly targeted (3). 
Among RAS family members, KRAS gene mutants are prevalent in human lung ADC, with mutation fre-
quencies of  15%–25% (4, 5). Accordingly, KRAS mutations constitute targets whose potential for improved 
intervention in lung ADC will be strengthened by determining critical downstream effectors.
ADCs are defined as cancers that begin in secretory cells. Among the numerous markers of  lung 
ADCs, mucins stand out as traits that define tumor origin. Indeed, even in ADC subtypes characterized 
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histochemically as nonmucinous by negative labeling with histochemical dyes such as periodic acid 
Schiff ’s stain, mucin expression is often abundant when tested using more sensitive immunolabeling 
and gene expression analyses (6). Furthermore, mucinous ADCs are associated with KRAS mutations 
and worse prognoses for patients (7–12). Nonetheless, aside from the established roles of  mucins as 
markers of  tumor type and clinical outcomes, the functional consequences of  mucins on lung ADC 
development are poorly understood.
Mucins can be divided into 2 main families: membrane-bound and secreted. Membrane mucins such 
as MUC1 and MUC16 are known cancer antigens (KL-6 and CA-125, respectively), and their functions in 
tumor growth, survival, and invasion are well studied (13, 14). By contrast, the polymeric mucins MUC5AC 
and MUC5B are abundant in the lungs, and their dysregulated expression and hypersecretion contribute 
to pathobiological features such as airway obstruction, infection, and tissue remodeling in nonneoplastic 
disorders of  the lung (15–17). In lung ADCs, polymeric mucins are strongly expressed (17, 18). Recent 
reports have begun to provide clinical associations between mucin expression and lung ADC outcomes (7, 
9, 19), including several studies showing that MUC5AC is significantly associated with worsened survival 
in lung ADC patients (9, 12, 20, 21). These clinical findings are further supported with potential molecular 
mechanisms identified in gene knockdown studies demonstrating that MUC5AC plays a role in lung ADC 
cell growth in vitro (22). The effects of  complete deficiency have not been tested in vitro or in vivo.
We recently generated lines of  Muc5ac and Muc5b gene–KO mice and identified critical but distinct 
roles for them in the lungs. MUC5B is abundant at baseline, and it is critical for pulmonary host defense 
under homeostatic conditions. Muc5b gene disruption results in chronic microbial infection and premature 
mortality (23). By contrast, MUC5AC is present at very low levels at baseline (24), and unlike MUC5B, it 
is dispensable for airway homeostasis (25). When MUC5AC is induced in models of  allergic inflammation, 
it is required for asthma-like airflow obstruction to occur (26), and its principal adaptive role appears to be 
to aid in helminth defense (27). Because Muc5ac is a nonessential gene that plays a causative pathophysio-
logical role in mouse lungs, and because human MUC5AC is associated with poor outcomes in lung ADC, 
we sought to determine the effects of  its expression on lung carcinogenesis.
Here, we tested the hypothesis that MUC5AC/Muc5ac expression is associated with the development and 
progression of  KRAS/Kras-driven lung ADC and that MUC5AC/Muc5ac deficiency reduces tumor develop-
ment. Using 2 independent human cohorts, we found at both mRNA and protein levels that MUC5AC is a 
significant determinant of  poor prognoses in patients with KRAS (but not EGFR) mutant lung ADCs. Fur-
thermore, using 2 unique mouse models, one with constitutive activation of  Kras and the other chemically 
induced with urethane, we also found, for the first time to our knowledge, that Muc5ac plays a functionally 
causative role in tumor development in vivo. In aggregate, our studies support a role for MUC5AC as an 
important target in KRAS-driven lung ADCs, which are common yet poorly treated with existing therapies.
Results
MUC5AC expression is associated with ADC compared with squamous cell carcinoma. On a randomized tissue 
microarray containing lung ADC (n = 53), adenosquamous carcinoma (ASC) (n = 3), and squamous cell 
carcinoma (SCC) (n = 21) patient specimens that were labeled immunohistochemically for MUC5AC and 
evaluated blindly to test for differences in staining, striking differences in MUC5AC protein were observed 
(Figure 1). Ordinarily, staining for MUC5AC is abundant in normal bronchial, submucosal gland, and prox-
imal bronchiolar epithelia of  central airways, but MUC5AC is scant or absent in terminal bronchioles and 
at bronchoalveolar junctions (Supplemental Figure 1; supplemental material available online with this arti-
cle; https://doi.org/10.1172/jci.insight.120941DS1). By contrast, in tissues containing ADC/ASC tumors, 
which are known to have a bronchoalveolar origin (18), MUC5AC staining was abundant (Figure 1A). 
Furthermore, although SCC tumors typically arise from transformation of  more central tracheobronchial 
airway regions, staining for MUC5AC was sparse and diffuse in SCCs (Figure 1B). Indeed, blinded evalua-
tion confirmed dramatically higher levels of  MUC5AC in ADC/ASC compared with SCC, with histologic 
scores (H-scores) that were 6.83-fold greater in ADC/ASC relative to SCC (P < 0.0001) (Figure 1C).
MUC5AC expression is associated with reduced overall survival in lung ADC patients. To test whether clini-
cal outcomes correlated with differences in MUC5AC levels like those described above, MUC5AC mRNA 
expression in ADC vs. SCC was analyzed using http://kmplot.com/analysis/ to perform a meta-analysis on 
1,541 patients (27, 28). Using global gene expression and mortality metadata stratified by median MUC5AC 
mRNA expression and corrected for sex and cancer stage, we observed a significant association with high 
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MUC5AC expression and reduced overall survival (OS). In ADC patients (n = 534), there was a hazard ratio 
of  2.0 (range 1.5–2.7) that supports a greater mortality risk in those with MUC5AC levels above the overall 
ADC median (Figure 1D). Further, stage I ADC patients (n = 371) also showed worsened OS when strati-
fied for high vs. low MUC5AC expression (Figure 1E; hazard ratio of  1.9, range 1.3–2.8; log-rank P = 0.001). 
By contrast, in SCC patients (n = 525), differences in mortality risk relative to MUC5AC expression were not 
observed (Figure 1F). Collectively, these data suggest a significant role for MUC5AC involvement, specif-
ically in lung ADC compared with SCC, and the findings provide additional evidence to support roles for 
MUC5AC at both early and late stages of  lung ADC. These data also suggest that there may be a significant 
association between differential expression of  MUC5AC and prognoses in these diseases. We thus sought to 
explore these associations causatively in mouse models of  lung cancer.
Muc5ac deficiency reduces tumor burden in urethane-induced carcinogenesis. Urethane is a known carcin-
ogen that elicits lung ADC following i.p. injection. After 10 weeks of  treatment, urethane significantly 
increased Muc5ac mRNA (Figure 2A), histochemically detectable mucin (Figure 2B), and Muc5ac pro-
tein levels (Figure 2C) in the lungs of  WT BALB/cJ mice. Having established an association between 
urethane exposure and Muc5ac levels, a functional role for MUC5AC in early-stage lung ADC was 
investigated using Muc5ac-null mice on a BALB/cJ background (Muc5ac–/–). At 10 weeks following the 
initiation of  tumorigenesis with urethane, lung tumor multiplicity was significantly decreased in the 
Muc5ac–/– compared with WT Muc5ac+/+ mice. Muc5ac–/– animals showed reduced tumor numbers on 
lung surfaces (Figure 2D) and significantly lower overall tumor area within lung tissues (Figure 2E), 
thereby providing functional evidence of  Muc5ac involvement in the development of  lung ADC. In 
addition, the protective effect of  Muc5ac gene deficiency persisted in mice examined 20 weeks after ure-
thane exposure, supporting a significant role for MUC5AC in lung ADC progression (Figure 2, D–G). 
This causative relationship was explored further by testing the relationships between MUC5AC gene 
expression and molecular markers of  lung ADC in human patients.
Figure 1. MUC5AC production is associated with human lung ADC and poor survival. (A–C) MUC5AC protein levels 
were analyzed immunohistochemically using human tissue arrays. Representative images of MUC5AC immunostaining 
in adenocarcinoma (ADC) (A) and squamous cell carcinoma (SCC) (B) are shown. Scale bars: 200 μm (low magnifica-
tion) and 10 μm (high magnification). (C) MUC5AC H-scores for ADC (n = 53) and adenosquamous (n = 3) (combined 
and included with ADC, red circles) were compared with SCC (n = 21, gray circles). MUC5AC levels were significantly 
higher in ADC tissues. Data are individual values with lines depicting medians ± 95% CIs. Significance was determined 
by the Wilcoxon rank sum test (61). P < 0.05. (D–F) Effects of MUC5AC expression on survival in ADC and SCC were 
tested using KM Plotter (http://kmplot.com/analysis/). MUC5AC expression was stratified to define high- (red) and 
low-expression (black) groups by median transcript levels. Kaplan-Meier survival plot and hazard ratio calculations were 
compared by multivariate log-rank analyses with sex and stage as covariates; P < 0.05. While sex was not significant, 
stage was strongly significant for ADC (log-rank P < 1 × 10–14). Significant effects of high MUC5AC gene expression were 
observed for all human lung ADC (D, n = 534, log-rank P < 0.0001) and for stage I ADC (E, n = 370, log-rank P = 0.001) 
samples. No differences were observed in SCC (F, n = 315, log-rank P = 0.62). For all groups in D–F, calculated hazard 
ratios were 2.0 (1.5–2.7) for all ADC, 1.9 (1.3–2.8) for stage I ADC, and 1.1 (0.8–1.5) for SCC.
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MUC5AC as a potential target for KRAS mutant lung tumors. KRAS gene mutations are among the most 
prevalent in lung ADC in humans, and urethane-induced lung carcinogenesis is primarily associated 
with Kras mutations in mice (29, 30). Therefore, the links between KRAS and MUC5AC expression and 
lung ADC were investigated. An independent cohort of  human lung ADC patients was analyzed to 
interrogate the links between MUC5AC gene expression, KRAS gene mutation status, and clinical out-
comes. MUC5AC mRNA expression was measured in surgically resected lung ADC samples from the 
Profiling of  Resistance patterns and Oncogenic Signaling Pathways in Evaluation of  Cancers of  the Tho-
rax (PROSPECT) cohort, comprising 150 patients who did not receive neoadjuvant therapy and whose 
detailed prognostic, genetic, and gene expression data have been collected (31). Patients were stratified 
based on median MUC5AC mRNA expression using above- and below-median levels of  expression to 
dichotomize high- and low-expressing populations, as was done for KM-plot meta-analyses, above (Fig-
ure 1E). In this independent population, greater-than-median MUC5AC expression was also significantly 
associated with worsened OS (Figure 3A, P = 0.003), and it was likewise associated with decreased 
disease-free survival (Figure 3B, P = 0.05). Furthermore, when PROSPECT study patients were further 
divided into subgroups based on KRAS gene mutation status, the effects of  high MUC5AC expression on 
survival were even more apparent. In KRAS-mutant lung ADC patients, there was a trend for association 
between MUC5AC expression and worsened OS (Figure 3C, P = 0.07), and there was a significant asso-
ciation between MUC5AC expression and worsened disease-free survival (Figure 3D, P = 0.02). Lastly, 
we also evaluated EGFR gene mutation status and MUC5AC expression for any associations; none were 
identified (data not shown). In aggregate, these data demonstrate that MUC5AC expression is associated 
with more aggressive clinical phenotypes in lung ADC, including a tight link between MUC5AC expres-
sion levels and outcomes in patients with mutations in the KRAS proto-oncogene. Having thus demon-
strated that KRAS -driven lung ADC and MUC5AC expression in lung ADC patients were associated, 
this relationship was interrogated in mice to test for causation.
Figure 2. Muc5ac is elevated in urethane-induced tumors, and Muc5ac-deficiency leads to reduced tumor burden. 
(A) Muc5ac mRNA expression is significantly elevated in response to urethane in WT mice at 10 weeks after urethane 
(n = 5 mice per group). *P < 0.05 between saline (Sal) and urethane (Ure) treatments determined by 2-tailed t test (n = 
5 mice for each treatment group). (B) Periodic acid fluorescent Schiff’s (PAFS) positive mucin staining (red) indicates 
increased mucins in urethane-treated WT lungs. (C) Mucin-positive tumors contain immunohistochemically detectable 
Muc5ac in WT lungs. (D) Surface tumor counts in Muc5ac-sufficient (Muc5ac+/+) and -deficient (Muc5ac–/–) mice 10 
and 20 weeks following the first urethane injection. Significant differences were observed between genotypes at both 
time points (10 weeks, n = 6 Muc5ac+/+, n = 8 Muc5ac–/– mice; 20 weeks, n = 14 Muc5ac+/+, n = 19 Muc5ac–/– mice). (E) 
Tumor areas within tissues were significantly lower in Muc5ac–/– mice compared with Muc5ac+/+ mice (10 weeks, n = 4 
Muc5ac+/+, n = 4 Muc5ac–/– mice; 20 weeks, n = 10 per genotype). Data are mean ± SEM in A, D, and E. P < 0.05, deter-
mined by 2-tailed t test. (F and G) Lung histopathology of Muc5ac+/+ and Muc5ac–/– mice. Arrowheads identify tumors. 
Scale bar: 100 μm in B and C, 1 mm in F and G.
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Lack of  Muc5ac suppresses Kras-driven lung cancer. A transgenic mouse model (CC-LR) was previously 
developed by our group (32) by targeting mutant Kras expression to mouse bronchiolar epithelia (see Meth-
ods). CC-LR mice harbor a glycine to aspartic acid mutation that is commonly found in human KRAS 
and that results in rapid development of  ADC in Kras mutant transgene–expressing mice (33). As was also 
observed in the urethane model above, Muc5ac gene expression (Figure 3E), mucin glycoprotein (Figure 
3F), and MUC5AC protein (Figure 3G) were induced in CC-LR mice.
To test the promoting role of  MUC5AC in lung cancer, we crossed CC-LR mice with Muc5ac-null 
mice to generate a Kras mutant mouse lacking Muc5ac (CC-LR/Muc5ac−/− mice). The lack of  MUC5AC 
in this triple transgenic line significantly inhibited lung cancer promotion in CC-LR mice compared with 
age- and sex-matched control CC-LR mice (CC-LR/Muc5ac+/+) with intact MUC5AC (Figure 4, A and 
B). Surface tumor numbers decreased by 2.5-fold (Figure 4B), and histologic tumor area also decreased 
robustly (~1.9-fold) (Supplemental Figure 2A). Tumor suppression caused by MUC5AC absence was 
further confirmed by reduction in the amount of  the mutant form of  KRAS (KrasG12D) protein in West-
ern blot analysis of  whole lung homogenate from CC-LR/Muc5ac–/– mice compared with age- and sex-
matched CC-LR/Muc5ac+/+ mice (Supplemental Figure 2B).
Further histopathologic examination of  the lung sections from CC-LR/Muc5ac–/– mice showed that most 
lung tumors remained at early stages of  development. Reduced tumor cell proliferation in CC-LR/Muc5ac–/– 
mice compared with CC-LR/Muc5ac+/+ controls was indicated by the presence of  fewer Ki67-expressing cells 
(Figure 4, C and D), and reduced tumor angiogenesis was detected by decreased presence of  the markers ERG 
(34, 35) and CD31 (Figures 4, E and F, and Supplemental Figure 3). Lastly, the CC-LR/Muc5ac–/– tumors had 
significantly less adjacent inflammatory cell infiltrates compared with CC-LR/Muc5ac+/+ mice (Figure 4A 
and Figure 5, A–C). The links between diminishments in MUC5AC- and KRAS-dependent carcinogenesis 
and tumor-associated inflammation suggest that a potential mechanism through which MUC5AC promotes 
lung ADC occurs through effects of  MUC5AC on pulmonary inflammatory responses in CC-LR mice.
Muc5ac-deficiency inhibits lung inflammation and STAT3 activation. Having previously shown that lung 
tumor promotion in Kras mutant tumors is associated with inflammation and activation of  the STAT3 path-
way (36), we compared inflammatory cell populations in the lungs of  CC-LR/Muc5ac–/– mice with age- and 
sex-matched CC-LR/Muc5ac+/+ mice. The absence of  Muc5ac changed the BALF inflammatory cell profile 
Figure 3. Muc5ac expression worsens both 
human and mouse lung cancer with KRAS 
mutations. (A–D) Human ADCs (A and B; n = 
152) and KRAS-mutant ADCs (C and D; n = 39) 
from the PROSPECT Cohort were stratified 
based on Muc5ac median mRNA expression 
(high, red; low, black). Patient subgroups were 
then analyzed for differences in overall and dis-
ease-free survival using the Kaplan-Meier meth-
od for estimation of survival probability and the 
log-rank test; P < 0.05. (E–G) KRAS mutant lung 
cancer was modeled in mice (CC-LR). Muc5ac 
gene expression from CC-LR mice was compared 
with control littermates by qPCR (n = 3 mice per 
genotype). (F) Periodic acid fluorescent Schiff’s 
(PAFS) positive mucin staining (red) indicates 
increased mucins in CC-LR mice lungs. (G) 
Mucin-positive tumors contain immunohisto-
chemically detectable Muc5ac. Data are mean ± 
SEM in E. P < 0.05 by 2-tailed t test. Scale bar: 
50 μm in F and 200 μm in G.
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of  CC-LR/Muc5ac+/+ mice with a predominant effect on the macrophage population (Figure 5A). To further 
verify the potential role of  MUC5AC on Kras-associated tumor inflammation, the levels of  proinflammato-
ry cytokines with known effects in mutant Kras-driven lung tumorigenesis were measured (36, 37). Muc5ac 
deficiency was associated with significant reductions in the levels of  cytokines IL-6 (Figure 5D) and IL-17 
(Figure 5E), as well as chemokine KC (Figure 5F), which we previously demonstrated to have important 
roles in mutant KRAS-driven lung tumorigenesis (36, 37). Immunohistochemical analysis of  lung tumor 
tissues for pSTAT3, the main IL-6–responsive transcription factor, also revealed a significant suppression of  
STAT3 pathway activation (Figures 5, G and H). One caveat with this observed reduction in inflammation 
in CC-LR/Muc5ac–/– mice is that reduced tumor burden is often associated with reduced inflammation.
Discussion
ADC is a subtype of  lung cancer that is prevalent, progressive, and lethal, with 5-year survival rates that 
rapidly fall below 60% as disease progresses beyond stage I (38). Activating KRAS mutations are found in 
around 30% of lung cancer overall (39), and they exist in the majority of  mucin-overexpressing ADCs (8, 
40–43). Moreover, it has been recently shown that histologic patterns of  mucin in lung ADC are associated 
with KRAS mutations (9, 10). Whole-exome sequencing also demonstrated significant increases in MUC5AC 
copy number in 11% of the ADC patients tested, further supporting studies on MUC5AC (44). The studies 
presented here investigated the mucin MUC5AC as a common marker in lung ADC and its role in human 
disease and in mouse models. Using independent cohorts of  human lung cancer patients, we determined that 
(a) MUC5AC protein is a specific marker of  ADC, (b) high MUC5AC mRNA expression was significantly 
Figure 4. Lack of Muc5ac suppresses Kras-induced lung tumorigenesis. (A) Histopathological appearance of lung 
tissue and (B) lung surface tumor number in CC-LR/Muc5ac+/+ and CC-LR/Muc5ac–/– mice at 14 weeks age (n = 12 
CC-LR/Muc5ac+/+; n = 26 CC-LR/Muc5ac–/– mice). Ki-67 (C and D) and ERG (E and F) positive cells in lung tissue of 
CC-LR/Muc5ac+/+ and CC-LR/Muc5ac–/– mice at the age of 14 weeks (n = 3 per genotype). Data in B, D, and F are mean ± 
SEM. P < 0.05 by 2-tailed t test. Scale bars: 200 μm in A and 50 μm in C and E.
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associated with reduced OS, and (c) the detrimental effect of  high MUC5AC expression on patient survival is 
linked to KRAS gene mutations. These association data linking MUC5AC to the development and progres-
sion of  lung ADC strongly suggest that MUC5AC is a key promoter of  carcinogenic progression that may 
provide a target for therapeutic intervention for a disease whose only effective treatment is surgery. This is 
further strengthened by our findings in 2 different mouse models — chemical and genetic — both of  which 
are dependent on activating Kras gene mutations (29, 30, 32) and, as we show in this study, on the expression 
of  the Muc5ac gene. Our finding that MUC5AC is an effector of  KRAS-driven lung cancer in mice may be 
of  additional importance, given the challenges associated with inhibiting KRAS in human patients. Here, we 
found that MUC5AC is a significant predictor of  poor survival and prognosis in human KRAS-mutant lung 
ADC, and it has a significant role in promoting Kras-mutant lung cancer in mice.
In lung ADC cell lines in vitro, MUC5AC gene expression is controlled by EGFR- and HIF-1–depen-
dent pathways (45), both of  which are important factors in lung carcinogenesis. However, several studies 
have concluded that EGFR mutations did not associate with MUC5AC protein expression in lung ADCs 
(20, 46–49). This discrepancy could reflect limitations of  in vitro tests in both cell lines and primary cul-
tures. It could also reflect heterogeneous mechanisms that regulate the localization of  MUC5AC overex-
pression in lung ADC, since its expression is in regions of  the distal lung where it is not normally localized 
(Supplemental Figure 1). The tumor-promoting effects of  MUC5AC in terminal bronchiolar and broncho-
alveolar regions could be mediated through extracellular or intracellular mechanisms, such as interactions 
between integrin β4 and MUC5AC (40). A gene regulatory network for mucinous ADC was also identified 
where transcription factors SPDEF and FOXA3 induced MUC5AC expression in human mucinous lung 
cancer cells with mutant KRAS (9). Additionally, the bronchoalveolar junction is the location of  the stem 
Figure 5. Lack of Muc5ac suppresses protumor lung inflammation and STAT3 pathway activation. (A) Total mac-
rophages, (B) lymphocytes, and (C) neutrophils, as well as levels of IL-6 (D), IL-17 (E), and KC (F) in lung lavage fluid 
of CC-LR/Muc5ac+/+ and CC-LR/Muc5ac–/– mice at the age of 14 weeks are shown (n = 6 for lavage cellular differen-
tials and n = 3 for cytokine analysis). (G and H) Representative photomicrograph (G) and quantitative analysis (H) of 
pSTAT3-positive cells in lung tissue of CC-LR/Muc5ac+/+ and CC-LR/Muc5ac–/– mice at the age of 14 weeks (n = 4 mice 
per group). Data are mean ± SEM. P < 0.05 by 2-tailed t test. Scale bar: 25 µm.
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cells for ADC (bronchioalveolar stem cells [BASCs] or bronchoalveolar stem cells) (50). Taken together, 
these findings point to potential pathways where future studies will focus on suppressing MUC5AC gene 
expression. Such interventions could be beneficial not only for slowing lung cancer progression, but also for 
potentially enhancing cancer prevention.
The extracellular space in respiratory tissues is sustained by the defensive functions of an effective muco-
ciliary apparatus. The normal functions of airway mucus include trapping and eliminating inhaled particles, 
recruited inflammatory cells, and dead resident cells and debris from the lungs (16, 45). While an effective mucus 
barrier is critical for protecting the lungs from injury, excessive mucin production — specifically overproduction 
of MUC5AC (15, 16) — in chronic obstructive pulmonary disease (COPD) can impair mucociliary clearance 
and contributes to COPD pathogenesis (16). COPD is a risk factor for lung cancer (51, 52), and lung ADC with 
mucin overexpression has higher malignancy potential and poorer prognosis than other types of lung cancer (7, 
9, 12, 19–21, 40). It is not clear whether a mucociliary defect tied to lung ADC can be explained directly by poor 
mucociliary functions in remodeled cancerous tissues. These should be explored in future studies.
In addition to extracellular effects of  MUC5AC overexpression, excessive or mislocalized expression 
of  MUC5AC could also drive cell intrinsic pathologies. ADCs derived from nonrespiratory epithelia, 
including those of  the breast, prostate, and pancreas, commonly overexpress mucins (14). These tissues 
are not exposed to the same particulate loads as the airways, which are exposed to 8,000–12,000 liters of  
air containing hundreds of  billions of  particles daily (53). A lack of  clear environmental stimuli suggests 
that intrinsic factors may mediate detrimental effects of  mucin overexpression in nonrespiratory ADC 
cell autonomously. Polymeric mucins, including MUC5AC, are extraordinarily large molecules whose 
synthesis requires tight regulation of  gene expression in the nucleus, complex processing to facilitate 
disulfide-mediated polymer assembly in the ER, specific programming for the elaboration of  O-linked 
glycans in the Golgi, and coordinated regulation of  the secretory and postsecretory fates of  mature 
mucin glycoproteins. Accordingly, there are numerous proteins whose expression parallels mucins, and 
whose functions are essential for protein homeostasis (proteostasis). Indeed, mucin overexpression or 
misfolding can have dramatic effects on cellular, organ, and host responses that result in inflamma-
tion, tissue remodeling, and disease pathogenicity (54). Along these lines, altered epithelial polarity and 
migration of  lung ADC cell lines have been directly linked to MUC5AC expression in vitro (40). Future 
studies testing the downstream cellular effects of  MUC5AC/Muc5ac expression may identify mechanisms 
in mouse and human lung ADCs that are potential targets for novel treatments.
Targeted therapies for lung ADCs are elusive. There are over a dozen primary oncogenic drivers that 
could be considered as therapeutic targets for NSCLC. Two targets whose prevalence of  mutations accounts 
for 25%–45% of  disease are EGFR and KRAS (4, 55, 56). While EGFR and some other rare targets have 
seen successful treatments develop, the more frequently mutated oncogene KRAS has remained a chal-
lenge. Options for direct inhibition of  KRAS, such as antisense RNA and small molecule inhibitors, have 
been tested with very little success (57–60). Therefore, targeting downstream effectors of  KRAS presents an 
innovative alternative approach to inhibit the detrimental effects of  this pathway in lung ADC. The data pre-
sented here show significant associations of  MUC5AC with human lung ADC and patient outcomes, and 
they further demonstrate in animal models that MUC5AC plays a causative role in lung ADC. Since Muc5ac 
is a nonessential gene in the airways whose expression is linked to pathophysiological obstruction (25), our 
finding puts MUC5AC as an alternative potential therapeutic target downstream to KRAS, as well as inde-
pendently of  KRAS, due to the reduction of  tumor development observed in the presence of  Kras mutations. 
Thus, targeting MUC5AC could be used in combination with a conventional cytotoxic drug or for improve-
ment of  newly available immunotherapeutic modalities (e.g., immune checkpoint blockade) (61, 62).
In summary, the studies reported here show, for the first time to our knowledge, that the polymeric 
mucin MUC5AC plays a significant role in the development and pathogenesis of  KRAS-induced lung 
ADC. Given the lack of  efficacious targeting and the poor outcomes for patients, therapies directed at 
downstream effectors such as MUC5AC could be beneficial. One approach may be to exploit transcrip-
tional networks that regulate MUC5AC gene expression, such as HIF, Notch, or Nkx2-1 (24, 63–67). In 
addition, manipulating pathways involved in mucin glycoprotein biosynthesis and secretion, or developing 
efficacious mucolytic treatments that allow for better elimination of  MUC5AC from the distal airways, 
could also prove beneficial. Along these lines, it will be crucial for such therapies to inhibit the detrimen-
tal effects of  mucus dysfunction while preserving, or even potentially promoting, the beneficial effects of  
mucus on lung homeostasis and airway defense.
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Methods
MUC5AC immunostaining in NSCLC patients. Tissue microarrays were obtained 
through approval from the University of  Colorado Cancer Center SPORE in Lung 
Cancer Tissue Bank. Tumor stage and histopathology was performed by a board 
certified pathologist (D.T. Merrick). The clinical characteristics of  the tissues used 
in this study are presented in Table 1. Tissues were immunolabeled with biotinylat-
ed mouse monoclonal anti-MUC5AC antibody 45M1 (Thermo Fisher Scientific), 
using streptavidin-linked HRP (Thermo Fisher Scientific) and 3,3’-diaminobenza-
dene (47) (Vector Laboratories) to stain MUC5B brown. Antibodies were diluted 
1:200 in 0.1% Tween 20/PBS and incubated on tissues for 1 hour at room tempera-
ture. Nuclei blue were counterstained with Meyer’s hematoxylin. All chemicals were 
obtained from MilliporeSigma, unless otherwise indicated.
Once these tissue microarrays were stained for MUC5AC, 4 reviewers (A.K. 
Bauer, C.M. Evans, D.T. Merrick, P.R. Mann) determined H-scores for all samples 
in a blinded manner. H-scores were determined by the percentage of  staining using 
a 1–3 scoring method with the following formula ([1 × (% cells 1+)] + [2 × (% cells 
2+)] + [3 × (% cells 3+)]) (68, 69). D.T. Merrick, a board-certified pathologist, 
reviewed any slide discrepancies. The distributions of  MUC5AC H-scores were 
compared between SCC and ADC/ASC samples using a Wilcoxon rank sum test.
Meta-analysis for comparison between MUC5AC expression in NSCLC subtypes and 
overall patient survival. The program kmplot.org (http://kmplot.com/lung; 2015 ver-
sion; Feb 1, 2017–March 1, 2017) was used to evaluate MUC5AC mRNA expres-
sion (217187_at) to the NSCLC subtypes, ADC (n = 534 patients) and SCC (n = 
524 patients), for OS, similar to Bauer et al., 2017 (70). This database uses publicly 
available data sets (Gene Expression Omnibus [GEO]; Cancer Biomedical Informat-
ics Grid [caBIG]; The Cancer Genome Atlas [TCGA]) from several human Affyme-
trix microarray platforms because these arrays have 22,277 probe sets in common 
(27). Briefly, the raw CEL files were MAS5 normalized using the Affy Bioconductor 
library (27, 28). Data were then analyzed using kmplot.org, which uses R (Biocon-
ductor package within kmplot.org) and the database PostgreSQL to integrate the 
gene expression and clinical data (27, 28). We performed a multivariate COX regression analysis for OS 
with the covariates stage and sex, as in Győrffy et al., 2013 (27), based on the clinical information avail-
able. For the stage I analysis with ADC patients (n = 371 patients), we performed a univariate analysis. 
Kaplan Meier survival plots and log-rank P values were then calculated in kmplot.com and graphed in 
GraphPad stratifying by the median values for the MUC5AC gene expression as the threshold for high 
and low expression.
Urethane-induced carcinogenesis. Five- to 6-week-old male Muc5ac-deficient mice (Muc5ac–/–) were gener-
ated from a breeding colony at the University of  Colorado animal facility. This line was previously back-
crossed >10 generations onto a congenic BALB/cJ strain background using strain-specific microsatellite 
marker–assisted analysis. Age-matched WT mice (BALB/cJ) were purchased from the Jackson Laboratory 
and allowed to acclimate for 1 week prior to studies. Animals were housed in a virus- and antigen-free 
room. Mice were fed irradiated mouse chow (Teklad, 2920X) and water ad libitum and housed in cages that 
were humidity- and temperature-controlled.
Mice were injected i.p. with either urethane dissolved in saline (1 mg per g body weight; Milli-
poreSigma) or with vehicle (saline) weekly for 7 weeks. Urethane and saline solutions were sterilized by 
passage through 0.2-μm filters (Thermo Fisher Scientific). Mice were euthanized 10 or 20 weeks after 
the first urethane injection by CO2 exposure, followed by exsanguination. The left lung lobe was then 
fixed for 48 hours using methacarn (60% methanol, 30% chloroform, 10% glacial acetic acid), a highly 
permeable noncrosslinking fixative (71, 72). Tumors were then enumerated and sized as described pre-
viously (32, 73–75).
MUC5AC expression in a mutant KRAS human cohort. MUC5AC mRNA expression was determined by 
array analysis (Illumina v3) of  surgically resected lung ADC from 150 patients that did not receive neoad-
juvant therapy. This cohort was obtained from the PROSPECT study, developed in 2006 at MD Anderson 
Cancer Center (31). MUC5AC mRNA expression from these patients was log2 transformed, and median 
Table 1. Patient demographics for tissue arrays
Parameter n (Percent)
Sex
     Female 40 (47.1)
     Male 45 (52.9)
StageA 
     Stage 1 51 (62.2)
     Stage 2 21 (25.6)
     Stage 3 10 (12.2)
SubtypeB
     Adenocarcinoma 53 (66.3)
     Adenosquamous 3 (3.8)
     Squamous cell
     Carcinoma 21 (26.3)
     Sarcomatoid 2 (2.5)
     Lymphoepithelioma-
     Like carcinoma 1 (1.3)
Tobacco Status 
     Current 35 (41.2)
     Former 33 (38.8)
     Never 9 (10.6)
     Unknown 8 (9.4)
Mutations 
     KRAS 18 (21.2)
     EGFR 10 (11.8)
     TP53 5(5.9)
AThree patients did not have staging. BFive patients 
were removed from analysis due to low tissue content 
on the slide.  
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expression was computed. We then dichotomized lung ADC patients based on median MUC5AC mRNA 
expression in the manner previously performed (76). Patients with relatively low expression displayed lower 
than the median MUC5AC levels, whereas patients with relatively high expression exhibited greater than 
the median MUC5AC expression levels. Of  these patients, those with KRAS mutations (n = 39 of  150) 
were then stratified based on MUC5AC expression in this same set of  patients.
Mutant Kras mouse model. CCSPCre/LSL-KrasG12D mice (CC-LR) were generated by crossing mice har-
boring an activating Kras allele (Lox-Stop-Lox-KrasG12D) with mice containing Cre recombinase inserted 
into the Scgb1a1 club cell secretory protein (CCSP), also called Secregatlobin-1a1, locus as previously 
described (32). Muc5ac–/– mice were developed on congenic C57BL/6J and BALB/cJ lineages as previ-
ously described (26). C57BL/6J congenic Muc5ac–/– mice were crossed to CC-LR mice and are referred to 
as CC-LR/Muc5ac–/–. Both male and female CC-LR/Muc5ac–/– were used for these studies, and littermate 
CC-LR/Muc5ac+/+ mice were used as controls.
At 14 weeks of  age, mice were anesthetized and sacrificed by CO2 inhalation or i.p. injection of  tribro-
moethanol (MilliporeSigma), and the lungs were infused with 10% buffered formalin (MilliporeSigma). 
The sections were then stained with H&E. The H&E-stained slides were examined by a pathologist blinded 
to genotype and treatment, and proliferative lesions of  the lungs were evaluated in accordance with the 
recommendations of  the Mouse Models of  Human Cancer Consortium (77).
Immunostaining. IHC staining was performed and evaluated for expression of  pSTAT3 (Tyr705) (1:250; 
Cell Signaling Technology, 91125), Ki-67 (1:200; Abcam, ab16667), CD31 (1:50, BD Biosciences, 550274), 
ERG (ETS-related gene; 1:250; Abcam, Ab92513), rabbit anti–mouse MUC5AC (78), and mouse anti–
human MUC5AC (biotinylated 45M1; 1:500; Abcam, ab212636). Heat-induced antigen retrieval was per-
formed using 10 mmol/l of  citrate buffer (pH 6.0) in a pressure cooker for 20 minutes. Immunoreactivity for 
IHC was detected using biotinylated IgG secondary antibodies specific for each primary antibody, followed 
by incubation with ABC kit (Vector Laboratories), and stained with DAB. Slides were counter-stained with 
Harris hematoxylin. Images were obtained at 4×, 20×, and 40× magnification by an Olympus BX60 micro-
scope with Image-Pro Plus (version 4.5.1.22) or on an Olympus BX63 microscope with cellSens (version 
1.18). The numbers of  labeled positive cells for each marker were quantitated as a fraction of  total tumor 
nuclei per high power field (40×) in at least 10 fields from 3–5 mice of  each group. Results were expressed 
as percentage of  positive cells ± SEM.
For fluorescent labeling of mucin, tissues from both urethane-treated and CC-LR mice were stained using 
a periodic acid fluorescent Schiff  (PAFS) staining procedure as described previously (79). Briefly, tissues were 
oxidized in 1% periodic acid (10 minutes), rinsed, treated with acriflavine fluorescent Schiff ’s reagent (0.5% acri-
flavine HCl, 1% sodium metabisulfite, 0.01 N HCl) for 20 minutes, rinsed in double deionized H2O, and rinsed 
2 × 5 minutes in acid alcohol (0.1 N HCl in 70% ethanol). Slides were then analyzed with fluorescence micros-
copy, with mucin granules showing red fluorescence and nuclei and cytoplasm showing green fluorescence (79).
As mucin labeling controls, lung tissues from urethane-treated Muc5ac–/– mice, saline challenged WT 
and Muc5ac–/– mice, and allergen challenged WT and Muc5ac–/– mice were used (Supplemental Figure 4).
Assessment of  lung tumor burden and inflammation in CC-LR and urethane model. In some mice, lung-sur-
face tumor numbers were counted. Then, lungs were prepared for histological analysis. H&E sections 
were prepared from 3–5 animals per group. Five randomly selected microscopic fields from peripheral 
and central regions of  the lungs were photographed, and the percentage of  the lung field occupied 
by tumors was measured by overlaying of  these images on a dotted grid as previously described (32). 
In other mice, lung-surface tumor numbers were also counted, and then bronchoalveolar lavage fluid 
(BALF) was obtained by sequentially instilling and collecting 2 aliquots of  1 ml PBS through a tra-
cheostomy cannula (32). The lungs were snap frozen and stored for future RNA and protein analysis. 
Total leukocyte count was determined using a hemacytometer, and cell populations were determined 
by cytocentrifugation followed by Wright–Giemsa (W&G; MilliporeSigma) staining. The remaining 
BALF was centrifuged at 1,250 g for 10 minutes, and supernatants were collected and stored at –80°C 
for further analysis.
Cytokines/chemokine measurement. The levels of  selected cytokines in the BALF were assessed using 
the MCYTOMAG-70 K assay (MilliporeSigma) according to the manufacturer’s instructions. Data 
were collected using a Luminex 100 (Luminex Corporation). Standard curves were generated using a 
5-parameter logistic curve fitting equation (StarStation V 2.0; Applied Cytometry Systems). Each sample 
reading was interpolated from the appropriate standard curve.
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Quantitative PCR analysis. Total RNA was isolated from whole lung according to the TRIzol reagent 
protocol (Thermo Fisher Scientific) and purified by E.Z.N.A. total RNA kit I (OMEGA) at MD Anderson 
and the Nucleospin RNA II kit (Macherey-Nagel) at the University of  Colorado. Reverse-transcription 
PCR (RT-PCR) was performed using the qScript cDNA SuperMix (Quanta Biosciences) at MD Anderson 
and using MMLV reverse transcriptase (Invitrogen) and oligo-dT (Invitrogen) at the University of  Colora-
do, following previous protocols (80). Quantitative PCR (qPCR) was performed according to a standard 
protocol using Muc5ac and Hprt-specific primers (Mm01276718_m1 and Hs99999901_s1, respectively) in 
a TaqMan Master Mix (Thermo Fisher Scientific). Products were amplified in 3 technical replicates on 
96-well plates and measured on an ABI Viia 7 PCR system (ABI). The expression of  individual genes was 
calculated and normalized with the ΔΔCt method.
Statistics. Summary statistics for cell counts, and cytokine levels in BALF, mRNA expression, and 
nuclear staining of  Ki-67, ERG, and pSTAT3 in tumors were computed within treatment groups, and 
unpaired 2-tailed t tests with adjustment for unequal variances and nonnormal distributions was per-
formed to examine the differences between the mean cell counts of  the groups. For tumor counts and 
tumor areas, comparisons of  groups were made using unpaired 2-tailed Student’s t test, and presented 
as mean ± SEM. Differences were considered significant for P < 0.05. Assessment of  disease-free sur-
vival was performed using Cox proportional hazard regression analysis, and the Kaplan Meier method 
for estimation of  survival probability.
Study approval. All animal use at University of  Colorado was conducted in facilities accredited by 
the Association for the Assessment and Accreditation of  Laboratory Animal Care, approved by the 
University of  Colorado IACUC, and following the Helsinki convention for the use and care of  animals, 
including pathogen free conditions. All animal use at MD Anderson was also conducted in facilities 
accredited by the Association for the Assessment and Accreditation of  Laboratory Animal Care, and 
mice were housed in specific pathogen-free conditions and handled in accordance with the IACUC of  
MD Anderson Cancer Center.
All human tissues used at the University of  Colorado were approved by the IRB at the University 
of  Colorado as exempt because the samples only included the use of  existing pathologic specimens 
that were publicly available and are identified to the investigator only by a Tissue Bank identifica-
tion number. These studies are in compliance with the Helsinki Declaration, including the additional 
amendments. For the samples from MD Anderson, patient data is publicly available from the PROS-
PECT cohort (University of  Texas MD Anderson Cancer Center) (43); these patient samples were 
deidentified and approved by the MD Anderson IRB.
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